Zacks: Analysts Anticipate CytomX Therapeutics, Inc. (NASDAQ:CTMX) Will Announce Quarterly Sales of $18.39 Million

Wall Street brokerages expect that CytomX Therapeutics, Inc. (NASDAQ:CTMX) will report $18.39 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $16.00 million and the highest is $20.00 million. CytomX Therapeutics reported sales of $16.61 million in the same quarter last year, which indicates a positive year over year growth rate of 10.7%. The business is expected to report its next earnings report on Thursday, August 5th.

According to Zacks, analysts expect that CytomX Therapeutics will report full year sales of $85.55 million for the current year, with estimates ranging from $72.12 million to $118.70 million. For the next financial year, analysts forecast that the business will post sales of $84.56 million, with estimates ranging from $74.00 million to $104.80 million. Zacks’ sales averages are an average based on a survey of analysts that follow CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 58.13% and a negative return on equity of 94.20%.

A number of research firms have recently commented on CTMX. JPMorgan Chase & Co. began coverage on CytomX Therapeutics in a report on Monday, March 29th. They set an “overweight” rating and a $14.00 price objective for the company. Jefferies Financial Group upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 29th. Finally, Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 7th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $11.94.

CTMX stock traded up $0.32 on Friday, hitting $8.23. 1,601,355 shares of the company were exchanged, compared to its average volume of 1,066,297. The stock has a market capitalization of $535.04 million, a price-to-earnings ratio of -6.92 and a beta of 0.74. CytomX Therapeutics has a twelve month low of $6.25 and a twelve month high of $11.29. The business’s fifty day moving average is $8.21 and its two-hundred day moving average is $7.77.

In related news, CEO Sean A. Mccarthy sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $7.49, for a total value of $749,000.00. Following the sale, the chief executive officer now directly owns 306,894 shares of the company’s stock, valued at $2,298,636.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.80% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP bought a new position in CytomX Therapeutics during the first quarter worth $263,000. Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $87,000. Strs Ohio grew its stake in CytomX Therapeutics by 37.6% during the 3rd quarter. Strs Ohio now owns 77,200 shares of the biotechnology company’s stock worth $513,000 after buying an additional 21,100 shares during the last quarter. XTX Markets LLC acquired a new stake in CytomX Therapeutics in the fourth quarter worth $93,000. Finally, Assenagon Asset Management S.A. lifted its stake in CytomX Therapeutics by 26.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 218,763 shares of the biotechnology company’s stock valued at $1,433,000 after buying an additional 45,887 shares during the last quarter. 77.87% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Featured Story: What Is Dividend Yield and How Do You Calculate It?

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.